|
|
Post by awesomo on Jul 27, 2018 9:35:18 GMT -5
I sent Tanner an email for addiional details on their program for Afrezza, and for clarity concerning the 2014 distribution & customer satisfaction information on their website. Always a good idea to just ask instead of assume. š I hope they provide a satisfactory answer, but the optics on this deal are absolutely awful. |
|
|
|
Post by straightly on Jul 27, 2018 9:36:08 GMT -5
Except these guys shipped 6,500 items for all their products in ONE YEAR.Ā Tanner is not the answer. I donāt believe āitemsā equates to āquantityā. Ā They probably shipped 6,500 different items or products or skuās. Got to be ASINs, if you know what I mean. |
|
|
|
Post by awesomo on Jul 27, 2018 9:36:21 GMT -5
Don't you think this deal signals a bit of desperation? Given the demands on Mike and his executive team, to devote valuable time to a deal such as this does not seem prudent? As far as driving sales in the United Stated, the recent ADA data is the only ammo Mike has. Your thoughts on if it will move the needle faster than what has been achieved in the past 12 months? I'm more thinking that the # of posts from you and awesomo regarding this minor good news signals a lot Yeah, because anyone critical is short. Get over yourself. Iād say anyone long that likes this PR is delusional. |
|
|
|
Post by goyocafe on Jul 27, 2018 9:43:02 GMT -5
The timing of this release and < 1 week notice of the quarterly call is worth contemplating. There is another shoe in play, or more details to follow. jmho
|
|
|
|
Post by wmdhunt on Jul 27, 2018 9:50:42 GMT -5
I have not seen "exclusive" anywhere. So this may be just another "distribution avenue". It all counts though. It may make logistics better and easier to sales forces and/or medics around the world. I am optimistic that the next corp meeting will provide details.
|
|
|
|
Post by tomtabb on Jul 27, 2018 10:03:48 GMT -5
Doesn't really make sense to me. If I were hiring a distributor for a foreign country, I would hire within the foreign country. I would think MNKD could make better deals with individual foreign distributors in addition to acquiring those distributors' expertise of the countries' rules and regulations.
|
|
|
|
Post by casualinvestor on Jul 27, 2018 10:06:44 GMT -5
I'm more thinking that the # of posts from you and awesomo regarding this minor good news signals a lot Yeah, because anyone critical is short. Get over yourself. Iād say anyone long that likes this PR is delusional. And anyone that repeatedly tries to hammer down anyone saying anything good about news either has an agenda or is just a bad person deep down that likes to stomp on people's happiness. Possibly both. You have 7 posts in an hour, not counting this one. |
|
|
|
Post by morgieporgie on Jul 27, 2018 10:07:45 GMT -5
Doesn't really make sense to me. If I were hiring a distributor for a foreign country, I would hire within the foreign country. I would think MNKD could make better deals with individual foreign distributors in addition to acquiring those distributors' expertise of the countries' rules and regulations. Reeks of desperation, to be honest. |
|
|
|
Post by awesomo on Jul 27, 2018 10:14:57 GMT -5
Yeah, because anyone critical is short. Get over yourself. Iād say anyone long that likes this PR is delusional. And anyone that repeatedly tries to hammer down anyone saying anything good about news either has an agenda or is just a bad person deep down that likes to stomp on people's happiness. Possibly both. You have 7 posts in an hour, not counting this one. My agenda is wanting this company to turn around, and Iām posting that Iām upset with this cryptic PR that does nothing for managemtnās credibility. Didnāt know only positivity was allowed on this board and nobody should take the opposing side. Please do share what you think is so good about this... |
|
|
|
Post by oldfishtowner on Jul 27, 2018 10:18:19 GMT -5
Also, their "About Us" page highlights 2014 distribution. COUNTRIES SUPPLIED: 75 ITEMS SHIPPED: 6,500 CUSTOMER SATISFACTION: 5,000 First off, it's extremely outdated. Second, those numbers are incredibly low and the "Customer Satisfaction" metric makes absolutely no sense. What kind of partnership is this? Update, from a June 2017 PR: " Tanner Pharma provides patients access to unlicensed medicines in over 130 countries where no other treatment options are available..."
In three years, then, Tanner seems to have significantly expanded its market.
|
|
|
|
Post by silentknight on Jul 27, 2018 10:19:39 GMT -5
It's impossible to know what this means but given the lack of details, the Street isn't going to give MNKD any love, nor should they. Previously, MNKD signed deals with localized suppliers for distribution. That certainly seems like a more logical move than partnering with a one-stop-shop for the entire world, especially with one with such a small track record.
Personally, I don't take it as inherently good news, but at least it's news. So far MNKD has proven itself to be fully incapable of moving the sales needle in a significant way towards a path to profitability, as they dilute repeatedly to pay down debt and create working capital to keep the lights on. They're not in a good situation and despite Mike's best efforts, things don't seem to be improving. While I applaud their work to try and get Afrezza into more markets, the results of the company's performance do absolutely nothing to inspire investor confidence, which is why the stock continues to suffer.
Me personally, I think Afrezza is a great product with no market, as we've seen over the last several years. As an investment, I think MNKD is dead money and I've sold most of my stock over the past year (at massive losses) to try and get out from under it. I still hold a few thousand shares but I've given up on them ever amounting to much.
Maybe Brazil or India pan out, but given what we've seen in the U.S. side of things, there isn't much to make one believe that this new partnership, nor anything else they're doing, will drive sales. I've been hoping and waiting for MNKD to prove me wrong for years. I'm still waiting.
|
|
|
|
Post by harryx1 on Jul 27, 2018 10:20:02 GMT -5
|
|
|
|
Post by oldfishtowner on Jul 27, 2018 10:30:19 GMT -5
We can speculate all we want about Tanner. On the face of it, if it is about revenue or sales of Afrezza, you have to ask the question, why? Or maybe it is , why not?
On the other hand, maybe it is more about Bourne Partners than Tanner. Either a relationship with Deerfield or potential investors in MNKD, who knows? But the deal makes more sense if there is more to the story.
|
|
|
|
Post by harryx1 on Jul 27, 2018 10:30:53 GMT -5
|
|
|
|
Post by compound26 on Jul 27, 2018 10:32:20 GMT -5
I have not seen "exclusive" anywhere. So this may be just another "distribution avenue". It all counts though. It may make logistics better and easier to sales forces and/or medics around the world. I am optimistic that the next corp meeting will provide details. agree with your observation. Here are a few of my observations on this: a. this distribution arrangement probably is not an exclusive distribution arrangement, as wmdhunt noted above. Note the language "The agreement names Tanner as a distributor of AfrezzaĀ® outside of the United States in regions the product is not yet registered." b. Further to the observation under item a. above, I would assume this arrangement is in addition to whatever partnership/ self-filing that Mannkind is working on (Europe, Canada, Mexico, China, Middle East), etc., as noted by Mike in previous conference calls/presentations. Mattās post on this probably is what the two parties are thinking of (i.e., where Mannkind has not signed a distribution agreement or filed for approval itself, Tanner Pharmacy will have the rights to distribute Afrezza to the customers there). c. Tanner Pharmacy/Bourne Partner probably is not as niche or small as some would think. See a few relevant reports below. 1. The Carlyle Group and Bourne Partners Form Phoenix Therapeutics to Build Global Pharma Company NEW YORK, NY and CHARLOTTE, NC ā Global alternative asset manager The Carlyle Group (NASDAQ: CG) announced today that it has formed a joint venture with Bourne Partners, a healthcare-focused investor, operator and investment banking firm, to build a global pharmaceutical platform. This new venture, known as Phoenix Therapeutics, will be owned by Carlyle Partners VI, a $13 billion U.S. buyout fund, with a minority investment from Bourne Partners. Leveraging the financial resources and experience of Carlyle and Bourne, Phoenix Therapeutics will look to operate a pharmaceutical platform built through acquisitions. Phoenix Therapeutics will consider a range of acquisitions, including product and asset acquisitions, corporate acquisitions and carve-outs. www.carlyle.com/media-room/news-release-archive/carlyle-group-and-bourne-partners-form-phoenix-therapeutics-build 2. Partner Therapeutics (PTx) Acquires LeukineĀ® from Sanofi www.prnewswire.com/news-releases/partner-therapeutics-ptx-acquires-leukine-from-sanofi-300591625.htmlTanner Pharma Group Signs a Distribution Agreement for Partner Therapeuticsā Product, LeukineĀ® www.tannerpharma.com/tanner-pharma-group-signs-distribution-agreement-partner-therapeutics-product-leukine/Since quarterly conference call is only a few days away, letās see what additional details Mannkind will provide regarding this distribution arrangement. |
|
